Other investigators previously demonstrated increased antitumor activity by combining NGR-TNF-α with melphalan, cisplatin, paclitaxel, or gemcitabine using various schedules and doses in mouse B16F1 melanoma, RMA-T lymphoma, TS/A mammary adenocarcinoma, and WEHI-164 fibrosarcoma [24], [28]. This evidence concerns the gene TNF and breast adenocarcinoma.